Showing results (241-250 of 329) with videos related to

Sort By:
Pageof 33
Journal of General Internal Medicine|December 15, 2023
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by SexMargaret K Yu, Priya Vart, Niels Jongs, et al.
Zhonghua Yi Xue Za Zhi|April 28, 2005
[Cardiovascular disease in Chinese chronic renal insufficiency patients-epidemiology survey]Fan-Fan Hou, Zhi-Gang Ma, Chang-Lin Mei, et al.
Zhonghua Yi Xue Za Zhi|June 14, 2005
[Epidemiology of cardiovascular risk in Chinese chronic kidney disease patients]Fan-fan Hou, Zhi-gang Ma, Chang-lin Mei, et al.
Science Translational Medicine|April 16, 2025
Condensation of cellular prion protein promotes renal fibrosis through the TBK1-IRF3 signaling axisTantan Long, Yumei Lu, Yuanyuan Ma, et al.
Metabolism: Clinical and Experimental|August 3, 2024
Cannabinoid receptor 2 plays a key role in renal fibrosis through inhibiting lipid metabolism in renal tubular cellsShan Zhou, Xian Ling, Ye Liang, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|July 15, 2023
Pentraxin 3 plays a key role in tubular cell senescence and renal fibrosis through inducing β-catenin signalingPei Luo, Haixia Zhang, Ye Liang, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 12, 2016
Elevated Homocysteine Concentrations Decrease the Antihypertensive Effect of Angiotensin-Converting Enzyme Inhibitors in Hypertensive PatientsXianhui Qin, Youbao Li, Ningling Sun, et al.
Cell Death and Differentiation|June 17, 2022
B7-1 mediates podocyte injury and glomerulosclerosis through communication with Hsp90ab1-LRP5-β-catenin pathwayJiemei Li, Jing Niu, Wenjian Min, et al.
The Lancet. Diabetes & Endocrinology|December 18, 2020
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trialDavid C Wheeler, Bergur V Stefánsson, Niels Jongs, et al.
The Lancet. Diabetes & Endocrinology|January 13, 2019
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trialsHiddo J L Heerspink, Tom Greene, Hocine Tighiouart, et al.
Pageof 33